REFERENCES
- Espinal-Ingroff A., Shadomy S., Gebhart R.J. In vitro Studies with R51211 (Itraconazole). Antimicrobial Agents and Chemotherapy 1984; 26: 5–9
- Graybill J.R., Williams D.M., Van Cutsen E., Drutz D.J. Combination therapy for experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Reviews of Infectious Diseases 1980; 2: 551–558
- Graybill J.R., Kaster S.R., Drutz D.J. Treatment of experimental murine aspergillosis with Bay n7133. Journal of Infectious Diseases 1983; 148: 989–996
- Graybill J.R., Ahrens J. R51211 (Itraconazole) therapy of murine cryptococcosis. Sabouraudia 1984; 22: 445–453
- Heeres J., Backx L.J.J., Cutsem J. Antimycotic azoles. Part 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. Journal of Medicine Chem. 1984; 27: 894–900
- Meyer R.D., Young L.S., Armstrong D., Yu B. Aspergillosis Complicating Neoplastic Disease. American Journal of Medicine 1973; 54: 6–15
- Pennington J.E. Aspergillus pneumonia in hematologic malignancy: improvements in diagnosis and therapy. Archives of Internal Medicine 1977; 137: 769–771
- Van Cutsem J., Van Gerven F., Van de Ven M-A., Borgers M., Jansen P.A.J. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrobial Agents and Chemotherapy 1984; 26: 527–534
- Williams D.M., Graybill J.R., Drutz D.J., Levine H.B. Suppression of cryptococcosis and histoplasmosis by ketoconazole in athymic, nude mice. Journal of Infectious Diseases 1980; 141: 76–80